| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| e-3810 | fibroblast growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.08 | phase 3 | inhibitor |
| e-3810 | fibroblast growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.08 | phase 3 | unknown |
| e-3810 | fibroblast growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.15 | phase 3 | inhibitor |
| e-3810 | fibroblast growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.15 | phase 3 | unknown |
| e-3810 | fibroblast growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.12 | phase 3 | unknown |
| e-3810 | fibroblast growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.12 | phase 3 | inhibitor |
| e-3810 | vascular endothelial growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 3 | unknown |
| e-3810 | vascular endothelial growth factor receptor 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 3 | inhibitor |
| e-3810 | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 3 | inhibitor |
| e-3810 | vascular endothelial growth factor receptor 3 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.09 | phase 3 | unknown |
| e-3810 | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.05 | phase 3 | inhibitor |
| e-3810 | vascular endothelial growth factor receptor 2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.05 | phase 3 | unknown |
| e-3810 | platelet-derived growth factor receptor alpha | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.06 | phase 3 | unknown |
| e-3810 | platelet-derived growth factor receptor beta | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
0.05 | phase 3 | unknown |
| click here to return to the previous page | ||||||||